Imatinib Mesylate for Children With Dermatofibrosarcoma Protuberans (DFSP)

被引：40

作者：

Gooskens, Saskia L. M. ^{[1
]}

Oranje, Arnold P. ^{[2
]}

van Adrichem, Leon N. A. ^{[3
]}

de Waard-van der Spek, Flora B. ^{[2
]}

den Hollander, Jan C. ^{[4
]}

van de Ven, Cees P. ^{[5
]}

van den Heuvel-Eibrink, Marry M. ^{[1
]}

机构：

[1] Sophia Childrens Univ Hosp, Erasmus MC, Dept Pediat Oncol Hematol, NL-3015 GJ Rotterdam, Netherlands

[2] Sophia Childrens Univ Hosp, Erasmus MC, Dept Pediat Dermatol, NL-3015 GJ Rotterdam, Netherlands

[3] Sophia Childrens Univ Hosp, Erasmus MC, Dept Pediat Plast Surg, NL-3015 GJ Rotterdam, Netherlands

[4] Sophia Childrens Univ Hosp, Erasmus MC, Dept Pathol, NL-3015 GJ Rotterdam, Netherlands

[5] Sophia Childrens Univ Hosp, Erasmus MC, Dept Pediat Surg, NL-3015 GJ Rotterdam, Netherlands

来源：

PEDIATRIC BLOOD & CANCER | 2010年 / 55卷 / 02期

关键词：

children; dermatofibrosarcoma protuberans; imatinib; treatment; CHILDHOOD; TUMORS;

D O I：

10.1002/pbc.22494

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Dermatofibrosarcoma protuberans (DFSP) is a rare malignant soft tissue tumor in children. DFSP is characterized by a specific fusion of the platelet-derived growth factor beta (POGF beta) with the collagen type 1 alpha 1 (COL 1 alpha 1) gene which renders these tumors responsive to targeted therapy with tyrosine kinase inhibitors, such as imatinib mesylate, as is reported in adults. In the current report, we describe the first small pediatric DFSP series, in which response to imatinib mesylate contributed to successful treatment outcome. Pediatr Blood Cancer 2010;55:369-373. (C) 2010 Wiley-Liss, Inc.

引用

页码：369 / 373

页数：5

共 16 条

[1] Congenital and childhood dermatofibrosarcoma protuberans: A case report and review of the literature [J].

Checketts, SR ;

Hamilton, TK ;

Baughman, RD .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2000, 42 (05) :907-913

[2]

Cohen MH, 2005, CLIN CANCER RES, V11, P12

[3] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

[4] Treatment of dermatofibroma sarcoma protuberans using modified mohs micrographic surgery: No recurrences and smaller defects [J].

Hancox, John G. ;

Ben Kelley ;

Greenway, Hubert T., Jr. .

DERMATOLOGIC SURGERY, 2008, 34 (06) :780-784

[5] Dermatofibrosarcoma protuberans in childhood and adolescence: Report of eight patients [J].

Jafarian, Fatemeh ;

McCuaig, Catherine ;

Kokta, Victor ;

Laberge, Louise ;

Ben Nejma, Bourouia .

PEDIATRIC DERMATOLOGY, 2008, 25 (03) :317-325

[6] Clinical and pathological features of pediatric dermatofibrosarcoma protuberans [J].

Keshen, TH ;

Cederna, PS ;

Savell, VH ;

Platz, CE ;

Chang, P ;

Ricciardelli, EJ .

ANNALS OF PLASTIC SURGERY, 1995, 35 (06) :633-637

[7] Current treatment options in dermatofibrosarcoma protuberans [J].

Lemm, Doreen ;

Muegge, L. -O. ;

Mentzel, T. ;

Hoeffen, K. .

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2009, 135 (05) :653-665

[8] DERMATOFIBROSARCOMA PROTUBERANS PRESENTING IN INFANCY AND CHILDHOOD [J].

MCKEE, PH ;

FLETCHER, CDM .

JOURNAL OF CUTANEOUS PATHOLOGY, 1991, 18 (04) :241-246

[9] Imatinib - A review of its use in chronic myeloid leukaemia [J].

Moen, Marit D. ;

McKeage, Kate ;

Plosker, Greg L. ;

Siddiqui, M. Asif A. .

DRUGS, 2007, 67 (02) :299-320

[10] Imatinib mesylate: An attractive alternative in young children with large, surgically challenging dermatofibrosarcoma protuberans [J].

Price, VE ;

Fletcher, JA ;

Zielenska, M ;

Cole, W ;

Viero, S ;

Manson, DE ;

Stuart, M ;

Pappo, AS .

PEDIATRIC BLOOD & CANCER, 2005, 44 (05) :511-515

← 1 2 →